{'fraction_non_alphanumeric': 0.030892448512585814, 'fraction_numerical': 0.016018306636155607, 'mean_word_length': 5.205673758865248, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Increased plasma levels of 6-oxo-prostaglandin F1 alpha, a stable metabolite of prostacyclin, in acute kidney transplant rejection.

In 30 patients after kidney transplantation, 6-oxo-PGF1 alpha was examined in unextracted plasma by a specific radioimmunoassay. The material was divided into three groups. Patients with acute transplant rejection showing the highest 6-oxo-PGF1 alpha levels, patients with delayed transplant rejection having significantly lower plasma values and a third group of patients with stable transplant function. In these patients the plasma 6-oxo-PGF1 alpha-values were below the lower limit of detection (70 pg/ml). The enhanced 6-oxo-PGF1 alpha during rejection crisis could be interpreted as a self protection mechanism of vascular tissue which is, however, not sufficient in many cases, to prevent the irreversible rejection of the transplant.